Pyruvate Kinase M2 Expression, but Not Pyruvate Kinase Activity, Is Up-Regulated in a Grade-Specific Manner in Human Glioma

Normal tissues express the M1 isoform of pyruvate kinase (PK) that helps generate and funnel pyruvate into the mitochondria for ATP production. Tumors, in contrast, express the less active PKM2 isoform, which limits pyruvate production and spares glycolytic intermediates for the generation of macromolecules needed for proliferation. Although high PKM2 expression and low PK activity are considered defining features of tumors, very little is known about how PKM expression and PK activity change along the continuum from low grade to high grade tumors, and how these changes relate to tumor growth. To address this issue, we measured PKM isoform expression and PK activity in normal brain, neural progenitor cells, and in a series of over 100 astrocytomas ranging from benign grade I pilocytic astrocytomas to highly aggressive grade IV glioblastoma multiforme (GBM). All glioma exhibited comparably reduced levels of PKM1 expression and PK activity relative to normal brain. In contrast, while grade I-III gliomas all had modestly increased levels of PKM2 RNA and protein expression relative to normal brain, GBM, regardless of whether they arose de novo or progressed from lower grade tumors, showed a 3–5 fold further increase in PKM2 RNA and protein expression. Low levels of PKM1 expression and PK activity were important for cell growth as PKM1 over-expression and the accompanying increases in PK activity slowed the growth of GBM cells. The increased expression of PKM2, however, was also important, because shRNA-mediated PKM2 knockdown decreased total PKM2 and the already low levels of PK activity, but paradoxically also limited cell growth in vitro and in vivo. These results show that pyruvate kinase M expression, but not pyruvate kinase activity, is regulated in a grade-specific manner in glioma, but that changes in both PK activity and PKM2 expression contribute to growth of GBM.

[1]  A. Guha,et al.  Targeting Metabolic Remodeling in Glioblastoma Multiforme , 2010, Oncotarget.

[2]  R. Bamezai,et al.  Human pyruvate kinase M2: A multifunctional protein , 2010, Protein science : a publication of the Protein Society.

[3]  B. Kefas,et al.  Pyruvate kinase M2 is a target of the tumor-suppressive microRNA-326 and regulates the survival of glioma cells. , 2010, Neuro-oncology.

[4]  K. Aldape,et al.  Nuclear PKM2 regulates β-catenin transactivation upon EGFR activation , 2011, Nature.

[5]  Eric A Bushong,et al.  Dedifferentiation of Neurons and Astrocytes by Oncogenes Can Induce Gliomas in Mice , 2012, Science.

[6]  L. Cantley,et al.  Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation , 2009, Science.

[7]  Z. Hall Cancer , 1906, The Hospital.

[8]  Steven Eschrich,et al.  Molecular and Cellular Pathobiology The Metabolomic Signature of Malignant Glioma Re fl ects Accelerated Anabolic Metabolism , 2012 .

[9]  J. Manley,et al.  Turning on a fuel switch of cancer: hnRNP proteins regulate alternative splicing of pyruvate kinase mRNA. , 2010, Cancer research.

[10]  M. Assanah,et al.  HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer , 2010, Nature.

[11]  C. Boschek,et al.  Pyruvate kinase type M2 and its role in tumor growth and spreading. , 2005, Seminars in cancer biology.

[12]  B. Davidson,et al.  Tumour M2-pyruvate kinase: a gastrointestinal cancer marker , 2007, European journal of gastroenterology & hepatology.

[13]  Russell G. Jones,et al.  Tumor suppressors and cell metabolism: a recipe for cancer growth. , 2009, Genes & development.

[14]  L. Parada,et al.  Malignant Glioma: Lessons from Genomics, Mouse Models, and Stem Cells , 2012, Cell.

[15]  Xueliang Gao,et al.  Pyruvate kinase M2 regulates gene transcription by acting as a protein kinase. , 2012, Molecular cell.

[16]  S. Baker,et al.  The PTEN/Akt pathway dictates the direct alphaVbeta3-dependent growth-inhibitory action of an active fragment of tumstatin in glioma cells in vitro and in vivo. , 2006, Cancer research.

[17]  Lynda Chin,et al.  Emerging insights into the molecular and cellular basis of glioblastoma. , 2012, Genes & development.

[18]  O. Warburg [Origin of cancer cells]. , 1956, Oncologia.

[19]  M. Brada Pathology and Genetics of Tumours of the Nervous System , 2001, British Journal of Cancer.

[20]  Jason W. Locasale,et al.  Evidence for an Alternative Glycolytic Pathway in Rapidly Proliferating Cells , 2010, Science.

[21]  A. Levine,et al.  The Control of the Metabolic Switch in Cancers by Oncogenes and Tumor Suppressor Genes , 2010, Science.

[22]  S. J. Darnton,et al.  The metabolic marker tumour pyruvate kinase type M2 (tumour M2-PK) shows increased expression along the metaplasia–dysplasia–adenocarcinoma sequence in Barrett’s oesophagus , 2004, Journal of Clinical Pathology.

[23]  T. Tanaka,et al.  The M1- and M2-type isozymes of rat pyruvate kinase are produced from the same gene by alternative RNA splicing. , 1986, The Journal of biological chemistry.

[24]  M. Gumińska,et al.  Tumor-specific pyruvate kinase isoenzyme M2 involved in biochemical strategy of energy generation in neoplastic cells. , 1997, Acta biochimica Polonica.

[25]  J. Nakamura,et al.  S6K1 plays a key role in glial transformation. , 2008, Cancer research.

[26]  F. Rösl,et al.  Alternative splicing of human papillomavirus type-16 E6/E6* early mRNA is coupled to EGF signaling via Erk1/2 activation , 2010, Proceedings of the National Academy of Sciences.

[27]  P. Mischel,et al.  Metabolic state of glioma stem cells and nontumorigenic cells , 2011, Proceedings of the National Academy of Sciences.

[28]  G. Semenza,et al.  Oncogenic alterations of metabolism. , 1999, Trends in biochemical sciences.

[29]  O. Mirzoeva,et al.  The Mre11/Rad50/Nbs1 complex interacts with the mismatch repair system and contributes to temozolomide-induced G2 arrest and cytotoxicity , 2006, Molecular Cancer Therapeutics.

[30]  B. Christensen,et al.  DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma. , 2011, Journal of the National Cancer Institute.

[31]  Ru Wei,et al.  The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth , 2008, Nature.

[32]  G. Semenza Oxygen sensing, homeostasis, and disease. , 2011, The New England journal of medicine.

[33]  G. Semenza mechanisms of disease Oxygen Sensing , Homeostasis , and Disease , 2011 .

[34]  W. Zwerschke,et al.  Effects of the human papilloma virus HPV-16 E7 oncoprotein on glycolysis and glutaminolysis: role of pyruvate kinase type M2 and the glycolytic-enzyme complex. , 2001, The Biochemical journal.

[35]  F. Ducray,et al.  IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.

[36]  H. Lehrach,et al.  No evidence for a shift in pyruvate kinase PKM1 to PKM2 expression during tumorigenesis , 2011, Oncotarget.

[37]  D. Gisselsson,et al.  Glial Progenitor-Like Phenotype in Low-Grade Glioma and Enhanced CD133-Expression and Neuronal Lineage Differentiation Potential in High-Grade Glioma , 2008, PloS one.

[38]  D. Sabatini,et al.  Cancer Cell Metabolism: Warburg and Beyond , 2008, Cell.

[39]  F. Oesch,et al.  Expression of pyruvate kinase M2 in preneoplastic hepatic foci of N-nitrosomorpholine-treated rats , 1999, Virchows Archiv.

[40]  Y. Wang,et al.  Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2 , 2011, Oncogene.

[41]  S. Schreiber,et al.  Perturbational profiling of a cell-line model of tumorigenesis by using metabolic measurements , 2005, Proceedings of the National Academy of Sciences of the United States of America.